Research and Development, Alder Hey Children?s NHS Foundation Trust, Eaton Road, Liverpool L12 2AP, UK.
BMC Med. 2013 Nov 7;11:238. doi: 10.1186/1741-7015-11-238.
Off-label and unlicensed (OLUL) prescribing has been prevalent in pediatric practice. Using data from a prospective cohort study of adverse drug reactions (ADRs) among pediatric inpatients, we aimed to test the hypothesis that OLUL status is a risk factor for ADRs.
A nested case?control study was conducted within a prospective cohort study. Details of all medicines administered were recorded, including information about OLUL status. The odds ratio for OLUL medicines being implicated in a probable or definite ADR was calculated. A multivariate Cox proportional hazards regression model was fitted to the data to assess the influence that OLUL medicine use had on the hazard of an ADR occurring.
A total of 10,699 medicine courses were administered to 1,388 patients. The odds ratio (OR) of an OLUL medicine being implicated in an ADR compared with an authorized medicine was 2.25 (95% confidence interval (CI) 1.95 to 2.59). Medicines licensed in children but given to a child below the minimum age or weight had the greatest odds of being implicated in an ADR (19% of courses in this category were implicated, OR 3.54 (95% CI 2.82 to 4.44). Each additional OLUL medicine given significantly increased the hazard of an ADR (hazard ratio (HR) 1.3 95% CI 1.2 to 1.3, P <0.001). Each additional authorized medicine given also significantly increased the hazard (HR 1.2 95% CI 1.2 to 1.3, P <0.001).
OLUL medicines are more likely to be implicated in an ADR than authorized medicines. The number of medicines administered is a risk factor for ADRs highlighting the need to use the lowest number of medicines, at the lowest dose for the shortest period, with continual vigilance by prescribers, in order to reduce the risk of ADRs.
超适应证和未注册(OLUL)处方在儿科实践中很常见。我们使用一项儿科住院患者不良反应(ADR)前瞻性队列研究的数据,旨在检验 OLUL 状态是 ADR 风险因素的假设。
在一项前瞻性队列研究中嵌套病例对照研究。记录所有给予的药物的详细信息,包括 OLUL 状态信息。计算 OLUL 药物与可能或确定 ADR 相关的比值比。使用多变量 Cox 比例风险回归模型对数据进行拟合,以评估 OLUL 药物使用对 ADR 发生风险的影响。
共给 1388 名患者给予 10699 个疗程的药物。与授权药物相比,OLUL 药物与 ADR 相关的比值比(OR)为 2.25(95%置信区间(CI)1.95 至 2.59)。在儿童中获得许可但给予年龄或体重低于最低要求的儿童的药物最有可能与 ADR 相关(该类别中有 19%的疗程与 ADR 相关,OR 3.54(95%CI 2.82 至 4.44)。给予的 OLUL 药物每增加一种,ADR 的风险就会显著增加(风险比(HR)1.3,95%CI 1.2 至 1.3,P <0.001)。给予的每一种额外的授权药物也会显著增加 ADR 的风险(HR 1.2,95%CI 1.2 至 1.3,P <0.001)。
OLUL 药物比授权药物更有可能与 ADR 相关。给予的药物数量是 ADR 的风险因素,这突出表明需要使用最低数量的药物,以最低剂量和最短时间使用,并由处方者持续警惕,以降低 ADR 的风险。